(BLCO) Bausch + Lomb - Ratings and Ratios
Contact Lenses, Lens Care, Eye Drops, Intraocular Lenses, Surgical Instruments
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 35.7% |
| Value at Risk 5%th | 52.9% |
| Relative Tail Risk | -9.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.04 |
| Alpha | -26.68 |
| CAGR/Max DD | 0.11 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.409 |
| Beta | 1.239 |
| Beta Downside | 1.342 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.07% |
| Mean DD | 20.56% |
| Median DD | 22.30% |
Description: BLCO Bausch + Lomb November 05, 2025
Bausch + Lomb Corp. (NYSE: BLCO) is an eye-health company operating globally across Vision Care, Pharmaceuticals, and Surgical segments. Its Vision Care line sells daily-disposable and therapeutic contact lenses, lens-care solutions, eye vitamins, and OTC drops for allergies, dry eye, and redness. The Pharmaceuticals division markets proprietary and generic drugs for post-operative care, glaucoma, ocular hypertension, dry eye, and retinal diseases. The Surgical segment supplies cataract-related devices-including intra-ocular lenses, phacoemulsification equipment, and consumables-for corneal, vitreous, and retinal procedures.
Key financial snapshots (FY 2023) show BLCO generating roughly **$2.5 billion** in revenue, with the Vision Care segment contributing about **55 %** of sales and delivering an operating margin near **15 %**. The company’s contact-lens business benefits from a **~5 % CAGR** in the global soft-lens market, driven by rising myopia prevalence and consumer preference for disposable lenses.
Sector-wide, aging demographics and increasing cataract surgery volumes underpin demand for BLCO’s Surgical products; the U.S. cataract surgery market is expected to exceed **$12 billion** by 2027, growing at **3-4 %** annually. Additionally, the broader eye-care market is sensitive to macro-economic factors such as discretionary spending on vision-correction accessories and insurance reimbursement policies for ophthalmic drugs.
BLCO is a subsidiary of Bausch Health Companies Inc., headquartered in Vaughan, Canada, and distributes its portfolio through a mix of direct sales forces and independent distributors.
For a deeper dive into BLCO’s valuation metrics and peer comparison, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-305.0m TTM) > 0 and > 6% of Revenue (6% = 298.6m TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA -0.98pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 19.27% (prev 21.93%; Δ -2.65pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 171.1m > Net Income -305.0m (YES >=105%, WARN >=100%) |
| Net Debt (4.64b) to EBITDA (509.0m) ratio: 9.12 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (354.2m) change vs 12m ago 0.08% (target <= -2.0% for YES) |
| Gross Margin 59.45% (prev 60.89%; Δ -1.44pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.39% (prev 34.66%; Δ 1.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.19 (EBITDA TTM 509.0m / Interest Expense TTM 421.0m) >= 6 (WARN >= 3) |
Altman Z'' -0.01
| (A) 0.07 = (Total Current Assets 2.85b - Total Current Liabilities 1.90b) / Total Assets 13.83b |
| (B) -0.06 = Retained Earnings (Balance) -873.0m / Total Assets 13.83b |
| (C) 0.01 = EBIT TTM 81.0m / Avg Total Assets 13.67b |
| (D) -0.28 = Book Value of Equity -2.07b / Total Liabilities 7.33b |
| Total Rating: -0.01 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.77
| 1. Piotroski 2.50pt |
| 2. FCF Yield -1.83% |
| 3. FCF Margin -3.91% |
| 4. Debt/Equity 0.77 |
| 5. Debt/Ebitda 9.12 |
| 6. ROIC - WACC (= -5.09)% |
| 7. RoE -4.75% |
| 8. Rev. Trend 90.21% |
| 9. EPS Trend -53.39% |
What is the price of BLCO shares?
Over the past week, the price has changed by -0.64%, over one month by +12.67%, over three months by +11.34% and over the past year by -4.77%.
Is BLCO a buy, sell or hold?
- Strong Buy: 3
- Buy: 3
- Hold: 8
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the BLCO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.3 | 1.6% |
| Analysts Target Price | 17.3 | 1.6% |
| ValueRay Target Price | 18 | 6.1% |
BLCO Fundamental Data Overview December 19, 2025
P/E Forward = 17.0068
P/S = 1.2015
P/B = 0.9355
P/EG = 0.6992
Beta = 0.617
Revenue TTM = 4.98b USD
EBIT TTM = 81.0m USD
EBITDA TTM = 509.0m USD
Long Term Debt = 4.92b USD (from longTermDebt, last quarter)
Short Term Debt = 28.0m USD (from shortTermDebt, last quarter)
Debt = 4.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.64b USD (from netDebt column, last quarter)
Enterprise Value = 10.62b USD (5.98b + Debt 4.95b - CCE 310.0m)
Interest Coverage Ratio = 0.19 (Ebit TTM 81.0m / Interest Expense TTM 421.0m)
FCF Yield = -1.83% (FCF TTM -194.5m / Enterprise Value 10.62b)
FCF Margin = -3.91% (FCF TTM -194.5m / Revenue TTM 4.98b)
Net Margin = -6.13% (Net Income TTM -305.0m / Revenue TTM 4.98b)
Gross Margin = 59.45% ((Revenue TTM 4.98b - Cost of Revenue TTM 2.02b) / Revenue TTM)
Gross Margin QoQ = 60.19% (prev 58.92%)
Tobins Q-Ratio = 0.77 (Enterprise Value 10.62b / Total Assets 13.83b)
Interest Expense / Debt = 2.04% (Interest Expense 101.0m / Debt 4.95b)
Taxrate = -733.3% (out of range, set to none) (22.0m / -3.00m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.51 (Total Current Assets 2.85b / Total Current Liabilities 1.90b)
Debt / Equity = 0.77 (Debt 4.95b / totalStockholderEquity, last quarter 6.43b)
Debt / EBITDA = 9.12 (Net Debt 4.64b / EBITDA 509.0m)
Debt / FCF = -23.86 (negative FCF - burning cash) (Net Debt 4.64b / FCF TTM -194.5m)
Total Stockholder Equity = 6.43b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.21% (Net Income -305.0m / Total Assets 13.83b)
RoE = -4.75% (Net Income TTM -305.0m / Total Stockholder Equity 6.43b)
RoCE = 0.71% (EBIT 81.0m / Capital Employed (Equity 6.43b + L.T.Debt 4.92b))
RoIC = 0.70% (EBIT 81.0m / (Assets 13.83b - Curr.Liab 1.90b - Cash 310.0m))
WACC = 5.79% (E(5.98b)/V(10.93b) * Re(10.58%) + (debt cost/tax rate unavailable))
Discount Rate = 10.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.48%
Fair Price DCF = unknown (Cash Flow -194.5m)
EPS Correlation: -53.39 | EPS CAGR: -25.76% | SUE: 0.09 | # QB: 0
Revenue Correlation: 90.21 | Revenue CAGR: 6.80% | SUE: 0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.07 | Chg30d=-0.016 | Revisions Net=+0 | Analysts=10
EPS next Year (2026-12-31): EPS=0.78 | Chg30d=+0.003 | Revisions Net=-3 | Growth EPS=+47.0% | Growth Revenue=+5.9%
Additional Sources for BLCO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle